Ghost Tree Capital’s Travere Therapeutics TVTX Stock Holding History

Ghost Tree Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-150,000	Closed	-$1.34M	–	74
2023 Q3	$1.34M	Buy	+150,000	New	+$2.12M	0.44%	55
2021 Q1	–	Sell	-475,000	Closed	-$12.9M	–	56
2020 Q4	$12.9M	Buy	+475,000	New	+$11.1M	2.88%	15
2019 Q2	–	Sell	-500,000	Closed	-$11.3M	–	49
2019 Q1	$11.3M	Hold	500,000	–	–	2.96%	12
2018 Q4	$11.3M	Buy	500,000 +150,000	+43%	+$3.73M	4.11%	7
2018 Q3	$10.1M	Buy	+350,000	New	+$10M	2.14%	17
2018 Q2	–	Sell	-314,367	Closed	-$7.03M	–	57
2018 Q1	$7.03M	Buy	+314,367	New	+$7.49M	1.42%	24
2016 Q4	–	Sell	-250,000	Closed	-$5.59M	–	96
2016 Q3	$5.59M	Buy	+250,000	New	+$4.76M	0.91%	39
2016 Q1	–	Sell	-200,000	Closed	-$3.86M	–	66
2015 Q4	$3.86M	Buy	+200,000	New	+$4M	1.58%	28

Other funds holding TVTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Ghost Tree Capital's TVTX Position: Q4 2023 in Review

Ghost Tree Capital sold out of Travere Therapeutics (TVTX) in Q4 2023, closing a stake of 150,000 shares — an estimated $1.34M sold.

Ghost Tree Capital first reported a position in TVTX in Q4 2015 and held it in 8 quarters. The position peaked at $12.9M in Q4 2020. 165 funds tracked by Wall St. Rank hold TVTX as of Q4 2023.

Ghost Tree Capital reported no remaining Travere Therapeutics position as of Q4 2023 after selling out during the quarter.
Ghost Tree Capital sold 150,000 Travere Therapeutics shares in Q4 2023, an estimated $1.34M.
Ghost Tree Capital first reported a position in Travere Therapeutics in Q4 2015 and held it in 8 quarters.
Ghost Tree Capital's Travere Therapeutics position peaked at $12.9M in Q4 2020.
165 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2023.

Based on Ghost Tree Capital's 13F filing for Q4 2023, filed 14 Feb 2024.